RE: Pfizer-geddon - One Man's ViewpointAs perhaps clarified in other posts, the Esperion rHDL compound did not kill anyone. It in fact is what gave credibility to this whole HDL field. Pfizer was a bit early and aggressive on the pricing no doubt, but the issue with Esperion was not efficacy, it was production. They were using an ecoli expression system which required an endotoxin purification step which stripped away precious yield for a compound that needed very high and already expensive doses. It was also using the Milano mutation which has different effects than wild type apoa-1.The development paths for a small molecule like RVX's and a biologic are very different. Aside from both relating to apao-1, I am not sure there is much cross over data that can be used. Also, Roger Newton did not purchase the Milano compound when he spun Esperion back out of Pfizer. That was done in late 2009 and sold to the Medicines Company albeit for a very small upfront. I think there is still an opportunity for a biologic based apoa-1 drug and there are a couple small biotech's working on them (one is in the process of going public right now which I am looking at) but these pose little competition to a successful RVX compound in my opinion.For those who know this field, my concern for RVX is what happened to Atherogenics. This is a very similar path and a lot of lessons can learned.